CDC finds lower RSV hospitalization rates for infants receiving prevention products
The Centers for Disease Control and Prevention May 8 released an analysis that found declines in hospitalizations for infants infected with respiratory syncytial virus during the 2024-2025 RSV season — the first with widespread availability of the maternal RSV vaccine and nirsevimab, a long-acting monoclonal antibody. Rates were 45% to 52% lower for infants less than 3 months old and 28% to 43% lower for those less than 8 months old. As of February, an estimated 66% of infants received either the maternal RSV vaccine or nirsevimab during the 2024-2025 season.
Related News Articles
Headline
The AHA and Epic are launching the Safer Births PPH Collaborative, a seven-month initiative designed to support hospitals in reducing postpartum hemorrhage…
Headline
The AHA Feb. 17 submitted a comment letter responding to the Centers for Medicare & Medicaid Services’ proposed rule that would prohibit hospitals…
Headline
A new blog shares key takeaways from the AHA’s Better Health for Mothers and Babies webinar series, where hospitals share how they are putting the initiative’s…
Headline
The Centers for Medicare & Medicaid Services announced Dec. 30 that it will no longer require states to report measures reflecting the immunization status…
Headline
The Centers for Disease Control and Prevention Jan. 5 updated the childhood vaccine schedule, recommending three categories of vaccines. The first category…
Headline
The Department of Health and Human Services Dec. 18 announced three regulatory actions related to the practice of “sex-rejecting procedures” on…